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Patient-reported outcome measures (PROMs) can provide valuable insights on the impact
of a disease or treatment on a patient’s health-related quality of life. In ophthalmology, par-
ticularly in dry eye disease (DED) and ocular surface disease (OSD), it is unclear whether
the available PROMs were developed using comprehensive guidelines. To address this, we
evaluated the methodological quality of studies assessing the psychometric properties of
PROMs in DED and OSD [PROSPERO registration number CRD42019142328].
Methods
Four databases were searched; reference list and citation searching of included studies was
also conducted. The COnsensus-based Standards for the selection of health Measurement
INstruments (COSMIN) checklist was used to appraise the quality of the studies evaluating
the psychometric properties of PROMs used in DED and OSD.
Results
The search strategy (S3 Table) retrieved 5,761 records, 573 duplicates were removed,
5,188 abstracts were screened and 127 full-text articles were retrieved for further review. Of
these, 118 full-text articles did not meet the eligibility criteria and were excluded. Reference
list and citation searching, identified an additional 8 articles bringing the total numbers of
papers reviewed to 17. In general, psychometric properties such as content validity, mea-
surement error and structural validity were not assessed by the studies included in this
review. Studies reviewing The Impact of Dry Eye on Everyday Life (IDEEL) presented with
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the highest quality scores together with the Ocular Surface Disease Index (OSDI)
questionnaire.
Conclusions
The quality of studies evaluating PROMs in DED and OSD was considered using the COS-
MIN standards. The majority of the studies evaluating PROMs included in this review did not
meet the recommended COSMIN criteria and the quality of the PROMs evaluated is not
assured. Further evaluation of their psychometric properties is required if these are going to
be used in clinical practice or research.
Introduction
Dry eye disease (DED) is a multifactorial disease of the anterior segment of the eye in which
the tear film homeostasis fails, leading to ocular symptoms, and signs such as ocular staining,
tear film instability and inflammation [1]. The most common cause of DED is inflammation
caused by a group of conditions known as ocular surface disease (OSD) [2] that include auto-
immune driven diseases such as Sjögren’s Syndrome or Ocular Mucous Membrane Pemphi-
goid. This can result in a range of eye symptoms including dryness, irritation, poor vision, sore
or fatigued eyes, and watering. Because of the nature of the symptoms, quality of life can be
affected and the individual may be unable to carry out activities of daily living including work,
socialisation, and driving [3], or maybe unable to sleep due to excessive dryness. DED has a
global prevalence ranging from 20% to 50% worldwide (depending on whether signs and
symptoms are studied separately or together), and has also been reported as one of the most
common reasons for eye consultations [4]. Gender (female), older age groups, ethnicity, com-
puter use and some medications (antihypertensives, antihistamines, and antidepressants) are
commonly reported risk factors [4].
There is a wide selection of treatments available for DED including lubricant eye drops,
ointments, gels, liposomal sprays, commercially available lid warming devices, anti-inflamma-
tory eye drops, therapeutic contact lenses, punctal plugs, and serum eye drops [5,6]. Lubricants
can range from simple formulations with the aim of increasing the tear film volume and reduc-
ing friction (e.g. hypromellose drops) to those which claim to restore parts of the tear film
structure (e.g. liposome drops). Agents with differing viscosities variably purport to act as pro-
tective shields in front of the ocular surface (gels) or oil content that can be used when asleep
(e.g. ointments). Biological tear substitutes are unlicensed medicines prepared from the
patient’s own blood (autologous serum eye drops) or from healthy donors (allogeneic serum
eye drops). These are reserved for patients with the severest form of DED and provide nutritive
benefits that replicate in part, the chemical constituents of the tear film which the commer-
cially available lubricants to address. Many patients symptomatically benefit from serum eye
drop use but access is limited due to regulations and funding restrictions. The nature of the
condition requires frequent administration of the topical treatments and this can itself bring
issues on patient well-being. The storage requirements such as keeping blood products frozen
(e.g. autologous and allogeneic serum drops), can be challenging particularly those who wish
to travel large distances using public transportation [7]. Therapeutic options are not curative;
DED is a chronic condition that can negatively impact on a patient’s quality of life because of
chronic pain, depression, and secondary sleep disorders [8]. Time to trade off analyses have
ranked living with DED similar to moderate angina or patients on renal dialysis [9].
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In the last few years, patient reported outcome measures (PROMs) have been increasingly
used in research and clinical trials to capture the efficacy of an intervention or a treatment
[10]. The use of PROMs in clinical trials has also been shown to identify additional benefits or
harms that might have been missed using clinical data alone [11]. PROMs are also important
for putting patients at the heart of clinical research and routine clinical practice [12]. They can
be used to track the condition from a patient’s perspective and to understand how their
health-related quality of life (HRQoL) is being affected by their health and therapeutic inter-
ventions [13]. Studies have also shown that PROMs that have been developed with input from
people living with the condition, are more robust and sensitive to change over time [14].
In ophthalmology, there are several PROMs focused on the impact of visual impairment
due to a condition (e.g. glaucoma, retinopathy, cataract), or tracking the outcome of refractive
surgery (cornea or lens surgery) and low vision rehabilitation [15]. However, there is uncer-
tainty about the psychometric quality of the PROMs available. In fact, in the field of dry eye
and ocular surface disease, it is unclear whether the available PROMs were developed follow-
ing guidelines such as those published by the Food and Drug Administration (FDA) [16] (S2
Table) and the European Medicines Agency (EMEA). This poses issues when using PROMs to
evaluate outcomes of novel devices or therapeutics where patient perceptions of their disease
and benefits of treatment are a critical outcome for the success of the technology being adopted
into clinical practice. Identifying the best PROMs to be used in clinical practice or research, we
need to evaluate the psychometric properties of PROMs available for use. Grubbs et al. [17]
reviewed some of the most common questionnaires in assessing the quality of life (QoL) in
DED in 2014. They concluded that the Ocular Surface Disease Index (OSDI) and the Impact
of Dry Eye in Everyday Life (IDEEL) were the most reliable measures. The term “ocular sur-
face disease” was not included in the search strategy. “Ocular surface disease” is defined as a
group of disorders, of diverse pathogenesis, in which disease results from the failure of mecha-
nisms responsible for maintaining a healthy ocular surface. The term indicates damage to the
surface layers of the eye and includes conditions with systemic comorbidities such as rheuma-
toid arthritis, Sjögren’s syndrome, mucous membrane pemphigoid, Steven-Johnson syn-
drome, atopic keratoconjunctivitis that can lead to ocular surface failure and blindness. Other
conditions include infective keratitis, and ocular surface tumours. While ‘Dry eye disease’ is a
feature of some but not all forms of ocular surface disease, systemic comorbidities amongst
those who have dry eye disease, can impact upon the patients’ tolerance of DED symptoms.
The difficulty in delivering arduous treatment regimens in these patients impact upon patient
wellbeing e.g. limited hand function can impinge upon their ability to self-administer eye
drops and increases dependence on others. This may not be generalisable to other forms of
ocular surface disease.
The Grubbs et al. [17] review did not use a validated tool such as the Consensus-based Stan-
dards for the selection of health Measurement INstruments (COSMIN) checklist to bench-
mark their evaluation of the included studies. Mokkink et al. [18] described COSMIN
guidelines as a useful tool for the evaluation of the methodological quality of studies assessing
the psychometric properties of PROMs. The guidelines were developed between 2006 and
2007 with input from a Delphi panel of more than 50 international experts who identified the
key items and measurement properties captured by the guidelines. The guidelines were also
updated in 2018 [19] when the authors decided to align with the Cochrane Collaboration for
systematic reviews of intervention studies [20] by including inadequate studies which were
previously excluded to avoid potential bias in their results. Additionally, the updated version
removed reference to reasonable gold standard regarding criterion validity and responsive-
ness. The COSMIN panel reached a consensus that currently no gold standard exists for
PROMs. Finally, the updated version removed references to sample size standards except for
PLOS ONE Patient outcomes in ocular surface disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0253857 August 9, 2021 3 / 23
adequate sample size for Content Validity, Structural Validity and Cross-cultural validity.
Using a comprehensive review such as the COSMIN guidelines can help determine which psy-
chometric properties were considered important and the best way to evaluate these using a
standardised approach. These guidelines are not only useful for research settings but clinicians
can also benefit by using this practical tool to evaluate the potential of outcome measurement
instruments in practice. Using these guidelines to evaluate the quality of the studies ensures a
consistent approach for evaluating the quality of studies evaluating PROMs and allows struc-
tured comparisons to be carried out.
Therefore, we present a systematic review of the quality of studies that report an evaluation
of the psychometric properties of PROMs developed for use in patients with dry eyes and ocu-
lar surface diseases following the latest COSMIN guidelines [18] (S1 Table).
Methods
Design
This systematic review was registered with PROSPERO (registration number
CRD42019142328). It was reported following the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA) checklist [21].
Search strategy. The following electronic databases were searched from inception: MED-
LINE (Ovid) and EMBASE (Ovid), PsycINFO (Ovid) and CINAHL Plus (EBSCO). All the rec-
ords were uploaded to Endnote X9 (Thomson Reuters). There were no restrictions in terms of
publication period or language.
The search terms included in the search strategy were agreed with two different clinicians
in the field of dry eyes and ocular surface disease. The sensitivity search filter developed by
Terwee et al. [22] was adapted and used on all the databases (S3 Table). In addition, papers
included in the full-text screening process were subjected to a hand search of reference lists
which has been conducted using Web of Science (WoS). The systematic review searches have
been done in 31.01.2020 and rechecked on 07.12.2020.
Selection of studies. Studies were included if they focused on PROMs used specifically in
patients with dry eyes and ocular surface disease. Additionally, the following eligibility criteria
were considered:
Inclusion criteria
1. Articles reporting PROM development in all dry eye and ocular surface disease
populations.
2. Articles reporting the assessment of one or more psychometric properties for PROM(s) in
all dry eye and ocular surface disease populations.
Exclusion criteria
1. Studies reporting the psychometric validation of clinician-reported instruments.
2. Trials or studies evaluating the effectiveness of a treatment or intervention where a PROM
questionnaire is used as an endpoint.
3. Editorials, reviews and conference abstracts.
All titles and abstracts were screened by 3 independent reviewers (AR, OLA and SCR). If an
abstract did not provide enough information to allow the reviewers to make a judgment and
take a decision, the abstract was included in the full-text screening process to avoid the risk of
missing potentially eligible articles. Full-text articles were retrieved for studies that met the eli-
gibility criteria and then reviewed by the same investigators.
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Reasons for exclusions at the full-text screening process were recorded. At any stage, if the
reviewers were unable to reach a consensus, a fourth reviewer was consulted (AS or SR).
A PRISMA flowchart summarises the process of selection (S1 Fig).
Data extraction. Two independent reviewers (AR and OLA) independently extracted the
data from each study using a data collection form, with disagreements resolved through dis-
cussion and, if necessary, consultation with one of the other reviewers (AS and SR).
Assessment of methodological quality. COSMIN guidelines were used in this review to
evaluate the quality of the studies evaluating the psychometric properties of PROMs used in
DED and OSD. Following the data extraction, the methodological quality of the papers consid-
ered in the systematic review was assessed by two reviewers (AR and OLA) using the latest ver-
sion of the validated COSMIN checklist [23]. The structure of the COSMIN checklist is divided
into 10 properties for evaluation: PROM development, content validity, structural validity, inter-
nal consistency, cross-cultural validity, reliability, measurement error, criterion validity, hypoth-
eses testing for construct validity and responsiveness. Every property can be rated individually
using the COSMIN 4-point scale as “very good”, “adequate”, “doubtful” and “inadequate”. Addi-
tionally, if a study has not considered one of the quality items rated with the COSMIN checklist,
the answer “data not available” has been recorded. The overall score of the quality is determined
by taking the lowest rating of any box considered (e.g. “the worst score counts” principle) [24].
In case of discrepancies between the reviewers (AR and OLA), the overall score was dis-
cussed with another reviewer (AS and SR).
Results
This section presents information on the measurement properties that were reported by the
individual studies including properties such as content validity, cross cultural validity, mea-
surement invariance, measurement error and criterion validity.
A total of 5,761 references were identified, duplicates were removed (n = 573) and 5,061 ref-
erences were excluded following the inclusion and exclusion criteria. Therefore, 127 full-text
records were assessed for eligibility, of which only 17 were reviewed. The selection process is
detailed in the PRISMA flow diagram (S1 Fig). A summary of the characteristics of the
included studies and PROMs were summarised in Table 1.
Table 2 summarises the characteristics of the included studies.
All the studies considered were single studies and measurement properties are summarised
in Table 3.
Table 4 includes the Updated COSMIN criteria for good measurement properties.
None of these PROMs were previously appraised using COSMIN guidelines according to
the COSMIN database and other available databases. The included studies have evaluated a
range of different properties such as development and validation, construct validity, psycho-
metric evaluation, minimal clinically importance differences, and reliability, etc.
In total, 3,350 subjects with or without DED diagnosis were recruited to the included stud-
ies (sample sizes ranged from 33 to 907). All participants were adults with ages ranging from
18 to 86 years. Studies were heterogeneous in terms of population demographic characteristics
(age, gender and ethnicity); however, the number of female participants included in the studies
was larger than the male participants (16 out of 17 studies included) this is consistent with the
aetiology of the condition. The Ocular Surface Disease Index (OSDI) (n = 3) and the Impact of
Dry Eye on Everyday Life (IDEEL) (n = 3), were the most frequently evaluated measures fol-
lowed by the Symptom Assessment in Dry Eye (SANDE) (n = 2), and the University of North
Carolina Dry Eye Management Scale (UNC DEMS) (n = 2). S1 Table provides information
about the COSMIN definition and criteria used in this study.
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Table 1. Characteristics of included studies.
















Patients with dry eyes USA/English 310 (81.6) 57.8 Not specified
2. Schiffman et al.
2000 [26]
Psychometric evaluation
study of dry eye symptoms









Dry eye for at least 3
months
3. Dougherty
et al. 2011 [27]
Psychometric evaluation
study of dry eye symptoms
(OSDI structural validity)
Patients with dry eye USA/English 172 (100) 63 (8) Not specified
4. Abetz et al.
2011 [28]
Development and validation
study of dry eye symptoms
















Dry eye symptoms 4
weeks previous the
inclusion
5. Fairchild et al.
2008 [29]
Psychometric evaluation
study of dry eye symptoms
Patients with dry eye USA/English 100 (70) 54 (17) Not specified






Patients with dry eye China/
Chinese
90 (72 50 (20–70) Not specified
7. Schaumberg
et al. 2007 [31]
Repeatability evaluation
study of dry eye syndrome
Patients with dry eyes USA/English 52 (92) 60 (50–71) Not specified
8. Amparo et al.
2015 [32]
Testing construct validity Patients with dry eyes USA/English 114 (62) 52 Not specified




















Patients with dry eyes USA/English 33 (68) 60.5 Not specified




study of blepharitis patients
Patients with blepharitis USA/English
and Spanish
907 (57) 62 (19–93) Not specified






















study of Meibomian Gland
Dysfunction patients
Patients with dry eye USA/English 69 (78) 53 (18) Not specified
14. Nichols et al.
2002 [38]
Reliability evaluation study of
dry eye syndrome
Patients with dry eye USA/English 75 (71) 46 (21–81) Not specified




Students and staff from Cardiff
University and University Hospital
of Wales
UK/English 452 (6) 34 (18–75) Not specified
(Continued)
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Ocular Surface Disease Index (OSDI) PROM
The OSDI questionnaire was developed by Allergan Inc. (Irvine, US) based on internal
research derived from the experience of patients and clinicians [26]. The original OSDI
version was comprised of 40 items covering eye discomfort, visual tasks and environmental
triggers then it was shortened to a 12 item version evaluating ocular soreness due to DED
and its relationship with visual function [26]. The 12-item OSDI has 3 domains of interest
namely: vision-related function (6 questions), ocular symptoms (3 questions) and environ-
mental triggers (3 questions). Score range from 0 to 100 (a higher score indicates a greater
impact). The questionnaire was designed to distinguish between healthy patients and
patients with DED.
PROM development and content validity. The development process and the develop-
ment of the content for items were not reported in any of the studies.
Structural validity and internal consistency. Only 2 out of 3 OSDI papers assessed fac-
tor analysis that reflects the structural validity of the construct being measured. Schiffman
et al. [26] and Dougherty et al. [27] performed exploratory factor analysis however limited
details were provided on the results. Schiffman et al. [26] conducted a confirmatory factor
analysis, whereas Dougherty et al. [27] performed Rasch analysis on the OSDI items. OSDI
items were considered to have an acceptable fit to the Rasch model and able to discriminate
between patients as demonstrated by the person separation index (PSI 2.16). Schiffman
et al. [26] did not perform Rasch analysis but reported a Cronbach’s alpha of 0.92 which is
considered acceptable within the COSMIN guidelines (95% Confidence interval range
0.89–0.94).
Reliability. Schiffman et al.[22] evaluated test-retest reliability (reproducibility) and they
reported an intraclass correlation (95% Confidence Interval) of 0.82 (range 0.73–0.88) [22].
Construct validity. OSDI showed moderate correlation with other considered PROMs
such as the McMonnies questionnaire (r = 0.67, p =<0.001) and the NEI VFQ-25 (r = -0.77, p
=<0.001) [26].
Responsiveness. Only Miller et al. [25] calculated the Minimal Clinically Important Dif-
ference (MCID) for the overall OSDI score using the Change with the clinician Global Impres-
sion (CGI) and the Subject Global Assessment (SGA) as anchors. Both CGI and SGA were
found significantly related (r = -0.3979 and r = -0.4200 with p<0.001, respectively).
Table 1. (Continued)











16. Ngo et al. 2013
[40]
Psychometric evaluation
study of dry eye symptoms




50 (80) 47 (20–86) Not specified
17. Frost et al.
1998 [41]
Development and validation
study of dry eye symptoms
and aspects of patients’ daily
life
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Table 2. Characteristics of the included studies.

















Assess dry eye symptoms
and its effects on vision-
related function/3 subscales







OSDI Likert scale ranging
from 0 to 4 points (Score
from 0 to 100)/Higher



















4. Impact of Dry Eye
on Everyday Life
(IDEEL) [28]
Assess the impact of dry eye




Dry Eye Impact on Daily





















5-point Likert scale for all
items except “eyedrop use”
that was scored “Yes” or
“No” (dichotomous)/DESB
higher scores means greater
bother
DEIDL higher scores
means less impact on QoL
DETS higher score means
greater satisfaction with
treatment
All (0–100) Self-administered 2 weeks












higher scores means greater
bother
(0–100) Self-administered 1 and 4
weeks




Assess the impact of dry eye




Dry Eye Impact on Daily





5-point Likert scale ranging
from “completely disagree”




means less impact on QoL
DETS higher score means
greater satisfaction with
treatment




Using visual analog scale to
assess frequency and
severity of dry eye
syndrome./2 different
modules:






Visual Analog Scale (VAS)/
Frequency: rarely to all the
time



















OSDI Likert scale ranging
from 0 to 4 points (Score
from 0 to 100)
SANDE Visual Analog
Scale (VAS)
Both focused on severity
and frequency of dry eye
symptoms
/ OSDI
Higher scores means higher
impact on QoL
SANDE Frequency: rarely
to all the time
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Table 2. (Continued)


















Using visual analog scale to
assess how bad are dry eye
symptoms and how they
affecting quality of life./






Scale from 1 to 10/
Frequency: not at all to
greatly





























Response range from “none
of the time” (0) to “all of
the time” (3)/From “none
of the time” (0) to “all of
the time” (3)





various eye symptoms and
how affecting quality of life./




Likert scale ranging from 0
(no symptom) to 4 (highest
frequency of symptom)/
From “never” (0) to
“always” (4)
and from “hardly bothered
me” (0) to “bothered me
very much” (4)













(0) to “severe” (9)






Visual function and quality
of life related to vision./
General health 1 item
Vision-related quality of life
15 items






(Score from 0 to 100)/
General health from
“excellent” (1) to “poor” (5)
Vision-related QoL from
“no difficult at all” (1) to
“stopped doing this for
other reasons or not
interested in doing this” (6)
Vision problems from “all
of the time” (1) to “none of
the time” (5)
0 to 100 Self-administered 2–3 weeks
15. Ocular Comfort
Index (OCI) [39]
Quick assessment of the
ocular comfort./Frequency









Scale from 0 to 100
From “no symptoms” (0) to
“most frequent/most severe
in the past week” (6)








Quick tracking of the
progression of dry eye
symptoms over time./
Frequency and severity of









Likert scale ranging from 0
to 3 and from 0 to 4
(question 3)
(Score from 0 to 28)/
Frequency
From “never” (0) to
“constant” (3)
Severity
From “no problems” (0) to
“intolerable” (4)
0 to 28 Self-administered 1 week
(Continued)
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Impact of Dry Eye in Everyday Life (IDEEL)
The Impact of Dry Eye on Everyday Life (IDEEL) questionnaire is a comprehensive dry eye
specific questionnaire developed by Alcon Research LTD (France) to evaluate symptom-
related bother, impact on daily life and treatment satisfaction in a population with dry eye
[28]. There are 57 items grouped into 3 different modules. The “Dry Eye Symptom-Bother”
module includes 20 items with a 4-point Likert scale (“not at all”, “slightly”, “moderately” and
“very much”) and frequency items score with a 5-point Likert scale. The “Dry Eye Impact on
Daily Life” module is composed of 3 modules including Impact due to dry eye on Daily Living
Activities (9 items), Emotional Impact (12 items) and Impact on Work (6 items). Daily living
and emotional impact are evaluated with a 5-point Likert scale. Work status consists of dichot-
omous responses (e.g. “Yes” or “No”). A higher the score means less impact on daily tasks,
work and emotion. Finally, the “Dry Eye Treatment Satisfaction” module is composed of 10
items which are divided into “Satisfaction with Treatment Effectiveness (6 items)” and “Treat-
ment-Related Bother/Inconvenience (4 items)” all the items are scored with a 5-point Likert
scale.
PROM development and content validity. Abetz et al. [28] provided a clear description
of the constructs being measured and the study population which consisted of dry eye patients
[non-Sjögren’s (non-SS) and Sjögren’s Syndrome (SS)] and a control group (made up of
healthy subjects). However, neither Fairchild et al. [29] and Zheng et al. [30] provided enough
information to adequately assess the PROM development process. Content validity was only
assessed by Abetz et al. [28] where the items were developed based on patients’ input (pilot
study with 16 patients) and then refined using clinicians opinions.
Structural validity and internal consistency. Abetz et al. [28] used exploratory factor
analysis (EFA) to identify and remove 55 items. Zheng et al. [30] performed the Kaiser-Meyer-
Olkin (KMO) Measure of Sampling Adequacy and the Bartlett test of sphericity before per-
forming EFA. Zheng et al. [30] results obtained demonstrated that the data were suitable to
perform EFA (KMO = 0.840: Bartlett = 1527.1, p< 0.001). The Rasch analysis was not per-
formed in any of the papers considered. Following the COSMIN guidelines, the sample size
considered should be at least 5 times the number of items included in the PROM. The number
of items included in the questionnaires analysed by Abetz et al. [28] (n = 57), Fairchild et al.
Table 2. (Continued)
























of deterioration, in vision,
safety at home, safety
outside the home, coping
with everyday life, inability






Scale from 0 (no problem)
to 5 (extreme problem)/
From “not at all” (0), “very
rarely” (1) “a little of the
time” (2) “a fair amount of
the time” (3) “a lot of the
time” (4) and “all the time”
(5)
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[29] (n = 20) and Zheng et al.[30] (n = 45) none of the study cohorts considered were numeri-
cally large enough to satisfy this requirement. Abetz et al. [28] tested internal consistency and
obtained a Cronbach’s alpha (� 0.70) that ranged from good (impact on daily activities, impact
Table 4. Updated COSMIN criteria for good measurement properties.
Measurement property Rating Criteria
Structural validity + CTT:
CFA: CFI or TLI or comparable measure>0.95 OR RMSEA
<0.06 OR SRMR <0.08
IRT/Rasch:
No violation of unidimensionality: CFI or TLI or comparable measure
>0.95 OR RMSEA <0.06 OR SRMR <0.08
AND
no violation of local independence: residual correlations among the
items after controlling for the dominant factor < 0.20 OR Q3’s < 0.37
AND





Rasch: infit and outfit mean squares� 0.5 and� 1.5 OR Z-
standardized values > -2 and <2
? CTT: Not all information for ‘+’ reported IRT/Rasch: Model fit not
reported
– Criteria for ‘+’ not met
Internal consistency +
At least low evidence for sufficient structural validity AND Cronbach’s
alpha(s)� 0.70 for each unidimensional scale or subscale
? Criteria for “At least low evidence for sufficient structural validity” not
met
–
At least low evidence for sufficient structural validity AND Cronbach’s
alpha(s) < 0.70 for each unidimensional scale or subscale
Reliability + ICC or weighted Kappa� 0.70
?
–
ICC or weighted Kappa not reported




SDC or LoA < MIC5
MIC not defined
SDC or LoA > MIC5
Construct validity + The result is in accordance with the hypothesis
? No hypothesis defined (by the review team)
– The result is not in accordance with the hypothesis
Cross-cultural validity
\measurement invariance
+ No important differences found between group factors (such as age,
gender, language) in multiple group factor analysis OR no important
DIF for group factors (McFadden’s R2 < 0.02)
? No multiple group factor analysis OR DIF analysis performed
– Important differences between group factors OR DIF was found
Criterion validity + Correlation with gold standard� 0.70 OR Area Under Curve (AUC)�
0.70
? Not all information for ‘+’ reported
– Correlation with gold standard < 0.70 OR AUC < 0.70
Responsiveness + The result is in accordance with the hypothesis OR AUC� 0.70
? No hypothesis defined (by the review team)
– The result is not in accordance with the hypothesis OR AUC <
0.70
The criteria are based on e.g. Terwee et al. [42] and Prinsen et al. [43] (Reproduced with kind permission from
Caroline Terwee, COSMIN).
https://doi.org/10.1371/journal.pone.0253857.t004
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on work and satisfaction with the treatment effectiveness) to excellent (“Dry Eye Symptom-
Bother” module). Zheng et al. [30] confirmed internal consistency across all 5 domains with
Cronbach’s alpha’s > 0.70 on the original IDEEL. It is not clear if Fairchild et al. tested for
internal consistency [29].
Reliability. Abetz et al. [28] demonstrated test-retest reliability using intraclass correlation
coefficient (ICC) ranging from 0.70 to 0.88 over the two time points. Neither Fairchild [29]
nor Zheng [30] papers reported information on reliability testing.
Construct validity. Abetz et al. paper [28] demonstrated low correlations for IDEEL with
two common and generic quality of life (QoL) questionnaires (Short Form 36-item and the
EuroQol (EQ) 5-item but was more highly correlated with the Dry Eye Questionnaire (DEQ)
on items related to eye dryness and eye discomfort (ranging from 0.21 to 0.83).
Zheng et al. [30] assessed known group validity by performing pairwise comparisons for
domains such as “Dry Eye Symptoms Bother” and “Impact on Daily Activities” reporting a sig-
nificant difference between patients belong to the mild (n = 24) and moderate (n = 36) DED
groups from those within the severe group (n = 30) (p< 0.05).
Responsiveness. Fairchild et al. [29] determined responsiveness by assessing changes in
self-assessed severity in patients with DED following the administration of eye drops for 4
weeks. The authors also used a response-operator curve (ROC) to determine clinically impor-
tant differences for the IDEEL”Symptom Bother” module. The clinically important difference
(CID) value which has minimised the overall error (CID at<12, 68% agreement, K = 0.34,
Effect size 1.14). After 4 weeks of drops usage, IDEEL-SB dropped among “improved” subjects
by -13.3 (SD = 10.9), “same” shifted by -4.7 (SD = 9.4), “worsened” changed by 1.4
(SD = 11.1).
Symptom Assessment iN Dry Eye (SANDE)
The SANDE questionnaire is composed of two questions determine how eye dryness and/or
irritation impact on patient symptomatology using a visual analogue scale (VAS) [31]. The
scale lengths 100mm, determines averages of frequency and severity symptoms for patients
having ocular discomfort or dryness. In version 1 of the questionnaire, the patient is asked to
mark on two given lines (frequency/severity) a lower score (left of the VAS) accounts for
“rarely/very mild” symptoms and a high score (right of the VAS) “all of the time/very severe”
symptoms. A second refined version of the questionnaire was created on which an anchor is
placed in the middle of each line (frequency/severity) to orient the patient on reporting based
on the last visit received [31]. On both lines, the extreme left accounts for “rarely”/“very mild”
and the extreme right for “all of the time”/“very severe” according to the change perceived
from the previous visit.
Reliability. Schaumberg et al. [31] reported a low ICC when comparing SANDE scores
before and after 2 months (range 0.12 to 0.39) while increased ICC values (range 0.45 to 0.76)
were reported when SANDE scores were compared closer (questionnaire obtained during visit
vs questionnaire emailed two days after the visit).
Construct validity. Schaumberg et al. [31] compared the SANDE questionnaire with the
degree of corneal staining and the reported use of eyedrops within all the consultations
recorded (initial, 2-month and 4-month follow-up): a weak correlation was found with the
clinical test (range 0.04 to 0.15) while a strong correlation was found considering the treatment
used (range 0.43 to 0.50). Amparo et al. [32] normalised the original scores when comparing
SANDE with OSDI as both questionnaire measure the symptomatology in a different way.
The authors obtained a significant correlation when the questionnaires were compared at the
baseline (r = 0.64, p< 0.0001) remarked also when considering mild to moderate dry eye
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patients (r = 0.37, p = 0.045) and severe dry eye patients (r = 0.39, p< 0.0001). Overall, both
questionnaires were correlated in terms of severity and frequency (r = 0.60, p = 0.0001) scores.
University of North Carolina Dry Eye Management Scale (UNC DEMS)
The UNC DEMS questionnaire was developed following the Patient-Reported Outcome Mea-
surement Information System (PROMIS1) guidelines [44]. UCM DEMS is a one-item graded
scale from 1–10 developed by ophthalmologists and people with DED. The questionnaire works
asking patients their dry eye symptoms which can include pain, burning, tearing, grittiness, “feel-
ing like something is in your eye”, and/or sensitivity to light. The symptoms bothersome increase
from the extreme left (1) up to the extreme right (10) based over the past week [33].
PROM development and content validity. Grubbs et al. [33] used the first seven PRO-
MIS1 standards for developing the questionnaire [44]. The authors clearly described the con-
struct by starting with a deep review of the literature on the field (DED symptoms and its
influence on QoL) and also added discussions with clinicians and patients suffering from the
conditions. In details, the development has considered an initial pilot study where 18 patients
with DED were asked to complete the questionnaire followed by a 15-minute cognitive inter-
view based on a question template of 13 items. Subjects enrolled in the study were able to
express their opinions on the comprehensiveness of the PROM. However, it is not clear from
the article if the interviewers were trained or not.
Reliability. Grubbs et al.[33] determined the re-test reliability of the UNC DEMS using
50 patients. The ICC was 0.90 (range 0.84–0.95) [26].
Construct validity. The comparison done by Grubbs et al. [16] with the OSDI question-
naire reported a significant correlation coefficient (Pearson r = 0.80, p<0.001). Although,
when compared inside the DED group enrolled the coefficient decreased to 0.69 but still signif-
icant (p<0.001).
Responsiveness. Hwang et al. [34] considered two methods to estimate minimal clinically
important difference (MCID). The linear regression was adjusted for both the number of days
since the last visit and the previous UNC DEMS score. The adjusted regression yielded a beta
coefficient value of -0.56; a confidence interval ranging from -0.99 to -0.13 (R2 = 0.43,
p = 0.013). The anchor method yielded an average change in the score for those rating their
symptom change to be “a little better/worse” was 1.09 (n = 11).
BLepharItIS Symptom (BLISS) measure. The study population was composed of
patients with blepharitis (e.g. anterior inflammation of the eyelid margins) [35].
The BLISS questionnaire is made of 13 items that assess symptoms related to ocular dis-
comfort and eye irritation caused by blepharitis (e.g. inflammation of the margin of the eye-
lids) [35]. All the presented items have been through an FDA Division of Transplant and
Ophthalmology Products review (more information can be found: https://www.fda.gov/about-
fda/center-drug-evaluation-and-research-cder/office-infectious-diseases-oid).
PROM development and content validity. The FDA review suggested that BLISS time
setting for the questions should be set as “today”. However, any additional information were
given on the content validity and its assessment.
Structural validity and internal consistency. Hosseini et al.[35] performed both explor-
atory and confirmatory factor analysis for all the items considered using PRO-MAX rotation
therefore confirmed considering categorical factor analysis using Mplus (Muthen & Muther,
Los Angeles, California, US). Sample size considered was very good with 907 subjects enrolled
with a clinical diagnosis of blepharitis.
Reliability. The “irritation scale” and “debris scale” returned a Cronbach alpha of 0.88
and 0.85 respectively. Test-retest reliability done with Spearman rank-order correlations
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ranged from 0.58 for “eyes that itch” to 0.74 for “dry eyes” when screening and beginning (7
days later) of the treatment visits were compared. These values represent moderate to good
reliability [45].
Construct validity. Spearman rank-order correlations between BLISS and OSDI were sig-
nificant with 0.63 and 0.41 for both “irritation” and “debris” scale versus 12-item OSDI (p’s<
0.001) [35].
Responsiveness. None of the included studies provided information on any of these mea-
surement properties.
Dry Eye-Related Quality-of-Life Score (DEQS) questionnaire
DEQS questionnaire is used for assessing the severity of dry-eye associated symptoms using a
score from 0 to 100, where 0 indicates no bother while 100 indicates a higher impact of symp-
toms on daily life [36]. DEQS is composed of 15 items and 2 subscales that are the “Bother-
some Ocular Symptoms” and “Impact on Daily Life”. These are scored using a 2-step
approach based on frequency and severity of the condition. The frequency is scored with a
5-point Likert scale ranging from 0 to 4 where 0 corresponds to no symptoms experienced and
4 highest frequency of symptoms). Severity is scored using a 4-point Likert scale ranging from
1 to 4 where 4 means the highest severity.
PROM development and content validity. The initial DEQS had 45 items which were
reduced to 35 items after consulting with patients with DED and expert clinicians on the field.
Participants were interviewed regarding their general impression, comprehensiveness, clarity
of the instructions, readability of the format and layout and opinions gathered from reading
the questionnaire.
Structural validity and internal consistency. A preliminary study was performed using
factor analysis. The results returned the presence of a 2-step scales known as “Bothersome
Ocular Symptoms” (6 items) and “Impact on Daily Life” (9 items). Internal consistency dem-
onstrated Cronbach’s alphas for “Impact on Daily Life” and “Bothersome Ocular Symptoms”
with a summary score of the two scales of 0.93 [36].
Reliability. Reliability of the DEQS was determined via test-retest in 116 DED subjects
who have completed the questionnaire between 8 to 21 days after the first sample was taken.
ICC correlation coefficients ranged from 0.81 to 0.93 [36].
Construct validity. Through known group comparison, the validity of the DEQS was
tested comparing DED subject with a control group of no-DED subjects. All DEQS items
(“Bothersome Ocular Symptom”, “Impact on Daily Life” and summary score) were signifi-
cantly correlated with the 25-item Visual Function Questionnaire (VFQ-25) with values ran-
ged from -0.20 to -0.77. Also, DEQS significantly correlated with the 8-item Short Form (SF-8)
questionnaire with the correlations ranged from -0.27 to -0.52 [36].
Responsiveness. Responsiveness was tested only in 10 DED subjects with punctal plug
insertion. The results revealed an improvement recorded with DEQS after the treatment con-
sidering the “Impact on Daily Life” (before 37.2 ± 27.7 vs after 20.7 ± 25.1, p = 0.04), “Bother-
some Ocular Symptoms” (before 49.6 ± 16.0 vs after 19.3 ± 13.0, p =<0.001) and summary
score (before 42.1 ± 21.6 vs after 20.0 ± 19.0, p = 0.001).
Meibomian gland dysfunction (MGD)-specific questionnaire
MGD condition is one of the main reason for developing DED. MGD-specific questionnaire is
composed of 24 items using a 0 to 9 scale for frequency and intensity. Additionally, the last
question is an open-ended question that read as “What was the most significant symptom you
have experienced with your eyes in the past month?” [37].
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PROM development and content validity. The development of the questionnaire used a
psychometric approach where two major surveys were considered to determine the number of
scale steps and its progression. The final version of the questionnaire has considered an ordinal
scale including patient’s symptoms during the last month (frequency and intensity).
Structural validity and internal consistency. Rasch analysis was performed in three dif-
ferent steps. Initially on all 24 items, then by reducing items first to 18 items and finally a
14-items questionnaire. Including 69 subjects and this demonstrated reasonable mean square
levels (INFIT MNSQ = 0.97; ZSTD = 20.2; OUTFIT MNSQ = 0.96; ZSTD = 20.2).
Reliability. Test-retest reliability was not performed.
Construct validity. The comparison between MGD-specific questionnaire and Schein
questionnaire (previously used in MGD patients [36]) revealed a significant Pearson correla-
tion at the baseline (r = 0.71, p<0.001) and at 6 months (r = 0.76, p<0.001).
Responsiveness. The authors measured the responsiveness of the questionnaire by
administrating it before and after 6-month of an eye drop treatment (mid-viscosity artificial
tears). MGD-specific questionnaire reported significant changes over the treatment:
58.4 ± 29.3 and 56.8 ± 22.3 (baseline), 30.6 ± 26.8 and 26.6 ± 24.4 (6 months) for the propylene
glycol–HP-guar and carboxyl-methyl-cellulose 0.5% treatments respectively (p = 0,001) [37].
National Eye Institute Visual Function Questionnaire 25-item (NEI-VFQ-
25)
NEI-VFQ-25 is a questionnaire designed to evaluate the visual function and its related QoL
[38]. It includes different areas based around visual function and wellbeing and also two items
to detect the level of patients tolerance to ocular irritation [38]. The total number of the items
included are 25 with a scoring system from 0 to 100 (a lower score indicates a greater impact).
Reliability. The authors assessed test-retest reliability over a short interval (e.g. between 1
and 2 weeks). They used kappa values above 0.60 to evaluate responsiveness items related to
“difficulty driving at night” and “staying at home because of vision” reported kappa values of
0.85 and 0.90 respectively. ICC coefficients ranged from 0.57 to 0.88 [38].
Ocular Comfort Index (OCI) questionnaire
The OCI questionnaire is composed of 12 items which measure not only ocular surface irrita-
tion but also the impact of DED on patients’ wellbeing and how effective are the treatment
considered. It is used in clinical trials [39].
PROM development and content validity. Development of the PROM started with a lit-
erature review and patient interviews.. However, it was not stated whether cognitive de-brief-
ing interviews took place. Given the limited information we were unable to assess whether the
content validity of the OCI met with the COSMIN criteria. Areas considered were: comfort,
dryness, grittiness, itching, pain, stinging, tiredness and visual stability that were focused on 15
questions. Except for comfort, all the areas included were assessed for frequency and intensity.
Ten versions of the OCI were produced and tested with the items in random order (except
comfort).
Structural validity and internal consistency. Unidimensionality was tested using unro-
tated factor analysis and fit to the Rasch model. The principal factor correlated with the indi-
vidual items ranging from 0.63 to 0.79. Additionally, Rasch analysis was performed using the
Rasch analysis software Winsteps (Winsteps, Chicago, IL, US) After the first Rasch analysis
was performed and 3 misfitting items were removed, the reduced 12-item scale showed good
fit. Fit statistics included INFIT MNSQ ranging from 0.86 to 1.17 and ZSTD from -2.0 to 2.4.
OUTFIT MNSQ ranging from 0.75 to 1.20 and ZSTD from 0.61 to 0.73. The separation indices
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in the OCI demonstrated a good level of person/item separation with a person separation of
2.66 indicating stable item difficulty estimates and discrimination between 3 levels of ability
across the scale [46] and an item separation of 11.12.
Reliability. Test-retest was performed to assess test reliability. 100 subjects repeated the
questionnaire 14 ± 7 days the authors reported 95% CI for the two-way random effects ICC of
the OCI was between 0.81 and 0.91.
Construct validity. OCI demonstrated significant correlations with the OSDI question-
naire ranging from 0.68 to 0.78 (p< 0.0001).
Responsiveness. OCI demonstrated that it could identify changes in symptoms before
and after eye drop treatments (28 days with either 0.3% carbomer 934 eyedrops or 0.18%
sodium hyaluronate eye drops with 65 subjects): 95% CI of the treatment difference accounted
for -5.5 to -8.0 units (p< 0.0001; paired t-test) [39].
Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire
SPEED questionnaire was developed to measure symptoms of ocular dryness and how they
change over time [40]. It is composed of 8 items and the final score range from 0 to 28.
Structural validity and internal consistency. Ngo et al. [40] applied Rasch analysis to
determine if the SPEED questionnaire fitted requirements of person and item fit requirements
for unidimensionality. The authors claimed that infit and outfit statistics met the requirement
for fit to the Rasch model but neither statistics were provided to support this claim. Besides,
the reported sample size was small (n = 50), and did not reach the suggested COSMIN require-
ments for adequate sample size in relationship to the number of SPEED items, and therefore
the likelihood of identifying misfit is limited should it occur.
Reliability. Test-retest was performed 1 week apart and the concordance correlation coef-
ficient (CCC) was 0.923 (95% confidence interval, 0.868–0.955) (where 1.0 is considered per-
fectly concordant test-retest data).
Construct validity. The area under the receiver-operator curves (AUC) comparing
SPEED and OSDI on 1 day after and 1 week after, was 0.928.
Vision Core Measure1 (VCM1)
VCM1, a vision-related quality of life (VQoL), is composed of 10 items that evaluate symptom-
atology and feeling of patients with visual impairment [41].
PROM development and content validity. Interviews with 38 visual impaired adults and
with 37 professionals and support workers were considered to generate the relevant items for
the questionnaire. Additionally, a literature review was performed. Content validity was
assessed together with face validity in 184 subjects with different visual limitations and social
backgrounds. The results gathered confirmed the high level of content validity [41].
Structural validity and internal consistency. Structural validity was not assed while the
internal consistency showed a Cronbach alpha coefficient of 0.93 for the 10 items selected
(pre-testing phase and pilot phase) [41].
Reliability. A pilot study with 92 subjects was conducted to determine reliability: test-
retest was performed between 7 and 38 days (median 17 days). The score ranged from 0.0 to
3.5 where the mean change in VCM1 score was +0.03 with a 95% confidence interval of -0.10
to 0.7.
Construct validity. Construct validity was assessed in 40 individuals. VCM1 score corre-
lated with all 129 items in the parent questionnaire and also the correlations with vision-spe-
cific measures were generally high that the one observed with the generic measures (Spearman
correlations equal to 0.60 or greater) [41].
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Discussion
Different PROMs are available in the field of ophthalmology and visual science [47]. However,
it is not completely clear which criteria have been considered when determining the quality of
studies evaluating PROMs for use in research and clinical practice. This is the first systematic
review to use the Consensus-based Standards for the selection of health Measurement INstru-
ments (COSMIN) Risk of Bias checklist in the assessment of the measurement properties of
PROMs used specifically in patients with or without DED and OSD.
The systematic review included 17 studies assessing 11 different PROMs used specifically in
this group of patients. The PROMs were used to understand the impact of the conditions
(DED, MGD or Blepharitis) on patients’ QoL in terms of severity and frequency of symptoms
or the effectiveness of treatments.
However, the use of the COSMIN Risk of Bias checklist [24], highlighted the fact that mea-
surement properties such as content validity, measurement error and structural validity were
not assessed for many of the PROMs included in this review. The development of many of
them was also not adequately reported making it difficult to assess the quality of these mea-
sures. Additionally, there was limited evidence of patient and public (PPI) involvement in the
development of the PROMs included in this review. PPI is essential in the development of
PROMs in order to make research more relevant and accessible to a wider public. As previ-
ously described by Wilson [12], patients input is crucial to provide better insights on how the
disease can affect QoL but also discuss which outcomes could be considered in research. This
can be achieved by considering large-scale surveys where patients’ experience can be compared
before and after treatment (e.g. cancer) or across different patients’ perspective. Therefore, as
suggested by Selby and Velikova [48], PPI should be present as a core feature in PROM design
and application.
Many of the studies were also based on reviews using classical test theory and this is
reflected in the COSMIN guidelines where common measurement standards (e.g. validity and
reliability are evaluated using factor analysis and Cronbach’s Alpha). For example, while the
content validity of the OCI could not be determined conclusively, it has good measurement
properties and may be used for studies after initial cognitive work is done with patients. How-
ever, increasingly modern psychometric approaches such as IRT and Rasch analysis are being
used to evaluate the extent to which interval level measurement and unidimensionality is
being achieved [49]. Many Rasch papers do not necessarily present CTT statistics as well as
IRT or Rasch indices.
As more studies are using only Rasch based methods for evaluating PROMs it might be nec-
essary to have additional guidance within the COSMIN guidelines to reflect this. This
approach especially in the development of new PROMs can evaluate additional psychometric
properties such as the evaluation of the scoring responses for disordered thresholds.
Previously, Grubbs et al. [17] reported that OSDI and IDEEL questionnaires were two of
the most common disease-specific PROMs in the ophthalmic fields, which were considered
valid and reliable. The OSDI questionnaire has been available and widely distributed for
decades [26]. It is well-known for its brevity and simplicity. However, we could not find any
detailed reports on its development which made it difficult to assess the extent to which its
content validity is supported by patients’ experiences of living with dry eye disease. However,
at the time OSDI was developed guidelines on the development of PROMs and in particular
making sure people living with the health condition are involved in the development was not
common. Content validity using patients’ experiences of living with a health condition is con-
sidered an important aspect of ensuring PROMs have content validity and this has been recog-
nised by the FDA and EMA [50]. Therefore, we would recommend that further research is
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required to ensure that the OSDI reflects patients’ experiences of living with dry eye
symptoms.
Based on our assessments using the COSMIN checklist, the IDEEL study presented with
the highest quality scores in terms of the evaluation of its psychometric properties [51]. They
also comply with current FDA guidelines (S2 Table) requiring PRO being used in labelling
claims to ensure that they can demonstrate content validity with input from patients lived
experiences of the health condition.
As noted in the review by Aiyegbusi et al, these COSMIN standards were developed within
the last decade, it is therefore understandable that most of the earlier studies included in our
review fared relatively poorly when judged against these exacting standards. This highlights
the need for a re-validation of these existing PROMs based on the current methodological
standards and recommendations.
Strength and limitations
This study is the first to undertake a systematic review of PROMs used in DED and OSD, in
accordance with the PRISMA [52] and COSMIN guidelines [24]. Following those scientific
approaches, has allowed us to conduct a structured and comprehensive evaluation of the mea-
sures. However, many of the PROMs considered were unable to fulfil the requirements and
the level of detailed reporting was found to be insufficient (e.g. missing data). Another critical
aspect observed was related to the populations considered which might be not appropriate for
the COSMIN guidelines evaluation (Number of items vs Sample size). However, as reported
by Isa et al. [53], COSMIN guidelines might show limitations when judging the methodologi-
cal quality of uncommon conditions (e.g. Blepharitis) where recruitment is limited because of
the rarity of the condition. Also, COSMIN guidelines while are assessing the quality of the
PROM’s measurement properties does not accommodate Rasch analysis and this should be
seen as a limitation too.
Conclusion
Using the COSMIN guidance it would appear that there are areas for improvement in the
study designs evaluating many of the PROMs currently being used in dry eye and ocular sur-
face disease. The majority of the studies included in this review did not meet the proposed cri-
teria and further validation work is required. Using quality PROMs in DED and OSD patients
could offer a unique perspective and provide valuable insights into patients’ experiences in
research and clinical settings. Consequently, it is not always possible to establish the quality of
the PROMs being evaluated and future studies should use COSMIN standards as a guide for
reporting the evaluation of their psychometric properties.
Future research
This systematic review could guide future PROMs research in the field of DED and OSD.
Researchers may design validation studies to address the gaps in evidence for all the PROMs
included in this review. Further evidence on the content validity of the measures including the
OSDI is needed.
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